Skip to main content
SpringerLink
Log in

Schedule-dependent modulation of the pharmacokinetics of MK-2206, an oral pan-AKT inhibitor: perspectives

  • Letter to the Editor
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Doi T, Tamura K, Tanabe Y et al (2015) Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 76(2):409–416

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Biondo A, Yap TA, Yan L et al (2011) Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors. J Clin Oncol 29:(suppl; abstr 3037)

  3. Yan L (2009) MK-2206: a potent oral allosteric AKT inhibitor [abstract #DDT01-1]. In: Proceedings of the 100th annual meeting of the American association for cancer research, Denver, CO, 18–22 Apr 2009

  4. Lu W, Defeo-Jones D, Davis L et al (2009) In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor [abstract #3714]. In: Proceedings of the 100th annual meeting of the American association for cancer research, Denver, CO, 18–22 Apr 2009

Download references

Author information

Authors and Affiliations

  1. Suramus Bio, Drug Development, 29th Main, 10th Cross, JP Nagar I Phase, Bangalore, Karnataka, 560078, India

    Nuggehally R. Srinivas

Authors
  1. Nuggehally R. Srinivas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nuggehally R. Srinivas.

Ethics declarations

Conflict of interest

The author(s) have no conflict of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Srinivas, N.R. Schedule-dependent modulation of the pharmacokinetics of MK-2206, an oral pan-AKT inhibitor: perspectives. Cancer Chemother Pharmacol 76, 1315–1316 (2015). https://doi.org/10.1007/s00280-015-2889-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-015-2889-2

Keywords

Search

Navigation